Sionna Therapeutics to Participate in the 2026 RBC Capital Markets Global Healthcare Conference

Sionna Therapeutics (Nasdaq:SION), a clinical-stage biopharmaceutical company focused on cystic fibrosis, will join the 2026 RBC Capital Markets Global Healthcare Conference.

Rhea-AI Summary

Sionna Therapeutics (Nasdaq:SION), a clinical-stage biopharmaceutical company focused on cystic fibrosis, will join the 2026 RBC Capital Markets Global Healthcare Conference.

Management will participate in a fireside chat on May 20, 2026 at 2:05 p.m. ET, with a live webcast and replay available via the company’s investor website.

Argus May 13 session

+5.32% close to close 1.1x rel. volume Open Argus

Details

News Market Reaction – SION

On May 13, the day this news came out, SION closed 5.32% above the previous close.

Data tracked by StockTitan Argus for the May 13 session.

Key Figures

Conference time: 2:05 p.m. ET Net loss: $26.8 million Prior-year net loss: $16.5 million +5 more

Conference time

2:05 p.m. ET

RBC Capital Markets Global Healthcare Conference on May 20, 2026

Net loss

$26.8 million

Q1 2026 net loss from 10-Q

Prior-year net loss

$16.5 million

Q1 2025 net loss comparison

R&D expenses

$19.0 million

Q1 2026 research and development expenses

G&A expenses

$10.6 million

Q1 2026 general and administrative costs

Cash & securities

$289.9 million

Cash, cash equivalents and marketable securities at March 31, 2026

ATM equity program

$250.0 million

At-the-market equity program size disclosed in 10-Q

ATM shelf registration

$250,000,000

Form S-3ASR shelf capacity with Leerink Partners

Historical Context

5 past events · Latest: Apr 27

5 events

1. Apr 27

   Clinical trial update

   24h Move

   +2.9%

   Announced completion of enrollment for Phase 2a PreciSION CF trial of SION-719.

2. Apr 07

   Investor conference

   24h Move

   -1.7%

   Planned one-on-one investor meetings at Raymond James 2026 Biotech Innovation Symposium.

3. Mar 02

   Earnings update

   24h Move

   -7.2%

   Reported higher 2025 net loss and increased general and administrative expenses.

4. Feb 23

   Investor conferences

   24h Move

   +1.7%

   Announced March 2026 investor fireside chats with webcast access for investors.

5. Feb 04

   Conference presentation

   24h Move

   -7.1%

   Planned presentation at Guggenheim biotech summit focusing on CFTR programs.

24h Move is the share-price change in the day after each event; other market factors may also have contributed.

Key Terms

at-the-market, form s-3, rule 10b5-1 trading plan, schedule 13g/a, +2 more

6 terms

at-the-market financial

"registered up to $250,000,000 of common stock for sale under an at-the-market sales agreement"

"At-the-market" is a method for companies to sell new shares of stock directly into the open market over time, rather than all at once. It allows companies to raise money gradually, similar to selling slices of a pie instead of the entire pie at once, which can help manage the sale's impact on the stock price. This approach gives investors a steady supply of shares while providing companies with flexible funding options.

form s-3 regulatory

"The shelf prospectus is an automatic Form S-3 registration that permits one or more offerings"

Form S-3 is a legal document companies use to register their stock sales with the government, making it easier and faster for them to raise money by selling shares to investors. It’s like having a pre-approved shopping list that lets a company quickly sell new shares when they need funds, without going through a lengthy approval process each time.

rule 10b5-1 trading plan regulatory

"shares at prices between $44.58 and $46.22 per share under a pre-arranged Rule 10b5-1 trading plan"

A Rule 10b5-1 trading plan is a pre-arranged schedule that allows company insiders to buy or sell stock at specific times, even if they have inside information. It helps prevent accusations of unfair trading by making these transactions look planned and transparent, rather than sneaky or illegal.

schedule 13g/a regulatory

"[SCHEDULE 13G/A] Sionna Therapeutics, Inc. Amended Passive Investment Disclosure"

A Schedule 13G/A is an amended public filing with the U.S. securities regulator that updates a previous Schedule 13G, disclosing when an individual or group holds a substantial (typically over 5%) stake in a company and is claiming a passive, non‑controlling intent. Investors monitor these updates because rising or falling holdings can signal changing confidence, potential future moves, or shifts in voting power — like watching a public ledger where large shareholders quietly adjust their positions.

schedule 13d/a regulatory

"[SCHEDULE 13D/A] Sionna Therapeutics, Inc. Amended Major Shareholder Report"

A Schedule 13D/A is an amended disclosure filed with regulators by an investor who already reported owning more than 5% of a company’s shares and needs to update their original filing. Think of it as a public status update that tells markets whether the investor’s ownership, plans, or source of funds have changed; such updates matter because they can signal a push for control, major strategic moves, or increased pressure on management, which can affect stock prices.

cftr medical

"dual-combination trial of SION-451 with two complementary CFTR modulators"

CFTR is a gene that makes a protein acting like a tiny gate in cell membranes to control the flow of salt and water; when the gate works properly it helps keep mucus thin and organs functioning. Investors care because mutations in CFTR drive serious diseases and create demand for diagnostics, drugs and long-term treatment revenue; progress or setbacks in therapies, approvals or patents directly affect company value.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

WALTHAM, Mass., May 13, 2026 (GLOBE NEWSWIRE) -- Sionna Therapeutics, Inc. (Nasdaq: SION), a clinical-stage biopharmaceutical company on a mission to revolutionize the current treatment paradigm for cystic fibrosis (CF), today announced that management will participate in a fireside chat at the 2026 RBC Capital Markets Global Healthcare Conference on Wednesday, May 20^th, 2026, at 2:05 p.m. ET.

A live webcast can be accessed in the ‘Investors’ section of Sionna’s website at https://investors.sionnatx.com/. A replay will also be available following the event.

About Sionna Therapeutics 
Sionna Therapeutics is a clinical-stage biopharmaceutical company on a mission to revolutionize the current treatment paradigm for cystic fibrosis (CF) by developing novel medicines that normalize the function of the cystic fibrosis transmembrane conductance regulator (CFTR) protein. Sionna’s goal is to deliver differentiated medicines for people living with CF that can restore their CFTR function to as close to normal as possible by directly stabilizing CFTR’s nucleotide binding domain 1 (NBD1), which Sionna believes is central to potentially unlocking dramatic improvements in clinical outcomes and quality of life for people with CF. Leveraging more than a decade of the co-founders’ research on NBD1, Sionna is advancing a pipeline of small molecules engineered to correct the defects caused by the F508del genetic mutation, which occurs in NBD1. Sionna is also developing a portfolio of complementary CFTR modulators that are designed to work synergistically with its NBD1 stabilizers to improve CFTR function. For more information about Sionna, visit www.sionnatx.com.

Sionna intends to use its Investor Relations website as a means of disclosing material nonpublic information and for complying with its disclosure obligations under Regulation FD. Accordingly, investors should monitor Sionna’s Investor Relations website, in addition to following Sionna’s press releases, SEC filings, public conference calls, presentations, and webcasts.

Media Contact 
Sarah Spencer
media@sionnatx.com

Investor Contact 
Juliet Labadorf 
ir@sionnatx.com 

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

When will Sionna Therapeutics (SION) present at the 2026 RBC Capital Markets Global Healthcare Conference?

Sionna Therapeutics will participate in a fireside chat on May 20, 2026 at 2:05 p.m. ET. According to the company, this session is part of the 2026 RBC Capital Markets Global Healthcare Conference.

How can investors access the Sionna Therapeutics (SION) webcast for the 2026 RBC Healthcare Conference?

Investors can access a live webcast of Sionna Therapeutics’ fireside chat in the Investors section of the company’s website. According to Sionna, a replay will be available following the event.

Will a replay be available for Sionna Therapeutics’ (SION) 2026 RBC Capital Markets conference presentation?

Yes, a replay of Sionna Therapeutics’ fireside chat will be available after the event. According to the company, both the live webcast and replay can be accessed via its investor relations website.

What type of company is Sionna Therapeutics (SION) participating in the 2026 RBC Healthcare Conference?

Sionna Therapeutics is a clinical-stage biopharmaceutical company focused on cystic fibrosis treatment. According to the company, it aims to revolutionize the current treatment paradigm for cystic fibrosis (CF).

Where is the investor information page for Sionna Therapeutics (SION) conference webcasts?

Sionna Therapeutics’ investor information, including the 2026 RBC conference webcast, is available at https://investors.sionnatx.com/. According to the company, both live and replay links are provided in the Investors section.